Healthcare

The February 2025 merger with Chemist Warehouse Group was a watershed moment for Sigma Healthcare (ASX: SIG). What had been a mid-sized pharmaceutical wholesaler became the controlling entity behind Australia's best-known pharmacy retail brand virtually overnight. The transaction — structured as a reverse takeover …

Few stocks on the ASX combine the profile of a defensive healthcare operator with the growth trajectory of a pure-play software business. Pro Medicus (ASX: PME) achieves exactly that. The company generates revenue almost entirely from multi-year software contracts with large hospital groups — …

After a prolonged period of headwinds — rising labour costs, European earnings softness, and balance sheet concerns — Ramsay Health Care (ASX: RHC) appears to be gaining traction on multiple fronts. The H1 FY2026 earnings result was broadly welcomed by the market, with operating …

Artrya is in focus because AI-driven healthcare has become one of the most talked-about themes for growth-oriented and small-cap investors. The promise of using artificial intelligence to improve the speed, accuracy and accessibility of medical diagnostics is compelling, and companies positioned at this intersection …

Few blue-chip ASX healthcare stocks have delivered as dramatic a storyline in 2026 as Cochlear (COH). In April, the company released a trading update revising its FY26 underlying NPAT guidance down to approximately A$290–330 million — a reduction of roughly 30% at the midpoint …

The catalyst that has put AYA on investor watchlists is the convergence of FDA regulatory clearances and an emerging US reimbursement pathway. In August 2025, Artrya received 510(k) clearance from the US Food and Drug Administration for its Salix Coronary Plaque module — following …

Several converging factors have placed 4DMedical on the radar of ASX healthcare investors in 2026. In January, the company announced it had secured more than US$100 million (approximately AU$150 million) through an institutional placement, reinforcing its ability to fund a sustained US commercial push. …